Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced that an additional overall survival analysis from the Phase 3 NAPOLI-1 study of ONIVYDE™ (irinotecan liposome injection), also known as “nal-IRI,” in post-gemcitabine metastatic pancreatic cancer will be presented at the American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium (ASCO GI), January 21-23, 2016, at the Moscone West Building in San Francisco.

Merrimack will also present under the “Trials in Progress” category posters on two ongoing front-line metastatic pancreatic cancer studies: ONIVYDE in combination with fluorouracil (5-FU) and leucovorin (LV), with or without the addition of oxaliplatin, versus nab-paclitaxel and gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma, and MM-141, also known as istiratumab, in combination with gemcitabine and nab-paclitaxel in front-line metastatic pancreatic cancer.

Poster Sessions

Session Title: General Poster Session B and Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Friday, January 22, 2016: 12:30 PM-2:00 PM and 5:30 PM-7:00 PM (PT)

  • Updated overall survival analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. (Abstract #417, Board L11)
  • Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. (Abstract #425, Board L19)
  • A randomized, open-label Phase 2 study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC). (Abstract #TPS482, Board O10)
  • A multicenter Phase 2 study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). (Abstract #TPS481, Board O9). (Original Source)

Shares of Merrimack Pharmaceuticals closed last Friday at $6.58, down $0.06 or -0.90%. MACK has a 1-year high of $13.84 and a 1-year low of $6.52. The stock’s 50-day moving average is $8.19 and its 200-day moving average is $9.65.

On the ratings front, Merrimack has been the subject of a number of recent research reports. In a report issued on December 24, Oppenheimer analyst Ling Wang assigned a Buy rating on MACK, with a price target of $15, which implies an upside of 128.0% from current levels. Separately, on December 23, Mizuho’s Eric Criscuolo maintained a Buy rating on the stock and has a price target of $13.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ling Wang and Eric Criscuolo have a total average return of -16.3% and -19.3% respectively. Wang has a success rate of 21.7% and is ranked #3572 out of 3610 analysts, while Criscuolo has a success rate of 14.3% and is ranked #3193.

Merrimack Pharmaceuticals Inc is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer.